Subcorneal Pustular Dermatosis

Back

Practice Essentials

Subcorneal pustular dermatosis (SPD), also known as Sneddon-Wilkinson disease, is a rare, chronic, relapsing pustular eruption characterized by subcorneal pustules that contain neutrophils on histopathology. See the image below.



View Image

Circinate plaques and pustules on nonerythematous base in a patient with subcorneal pustular dermatosis.

Signs and symptoms

Patients typically present with a history of a relapsing pustular eruption involving the flexural areas of the trunk and proximal extremities. Individual pustular lesions arise within a few hours. Pruritus and irritation can occur but are not usually prominent symptoms.

The classic lesion has been described as a "half-and-half" blister, in which purulent fluid accumulates in the lower half of the blister. New eruptions of pustules tend to coalesce and often form annular, circinate, and serpiginous patterns.

See Presentation for more detail.

Diagnosis

The workup includes the following:

See Workup for more detail.

Management

Dapsone is the treatment of choice. Acitretin should be considered as an alternative or additional treatment for those who are intolerant of, or unresponsive to, dapsone.

Phototherapy alone or in combination with dapsone and/or retinoids can be effective at controlling SPD.

See Treatment and Medication for more detail.

Background

Subcorneal pustular dermatosis (SPD) was first described by Sneddon and Wilkinson in 1956.[1, 2] This condition is more common in middle-age and older women but has been reported to occur also in children.[2, 3, 4, 5] Clinical findings are discrete, flaccid pustules or grouped vesicles that present predominantly on the flexor surfaces. In rare cases, unusual involvement of the face, palms, and soles has been described.[6]

Despite marked improvement in investigation techniques, the pathogenesis of this entity is still controversial. Direct and indirect immunofluorescence results are commonly negative in SPD. These findings suggest that SPD may not be an autoantibody-mediated disease. However, it was found that some patients with SPD show epidermal intercellular immunoglobulin A (IgA) deposits on direct and indirect immunofluorescence, which places them in the group of IgA pemphigus.[4, 7]

SPD has been described in association with IgA monoclonal gammopathies,[8, 9, 10] multiple myeloma,[11] and inflammatory diseases such as rheumatoid arthritis (RA)[12, 13] and Crohn disease.[14, 15]

According to some authors, SPD can be classified as one of the neutrophilic dermatoses together with pyoderma gangrenosum, Sweet syndrome, and erythema elevatum diutinum,[16] whereas others classify it within the group of autoinflammatory pustular neutrophilic diseases, together with pustular psoriasis variants.[17] In addition, it must be noted that autoimmune intercellular IgA dermatosis with autoantibodies to desmocollin is almost indistinguishable from classic SPD, which makes the nosologic classification of this entity remain controversial.[7]

Pathophysiology

The exact pathophysiology of subcorneal pustular dermatosis (SPD) is unknown. The accumulation of neutrophils in the subcorneal layer suggests the presence of chemoattractants in the uppermost epidermis, but the stimulus for these chemoattractants was not found. Interleukin (IL)‒1 beta, IL-6, IL-8, IL-10, leukotriene B4, and complement fragment C5a are neutrophil chemoattractants that have been found at increased levels in scale extracts of patients with SPD compared with that of controls. Tumor necrosis factor (TNF)‒alpha levels have been found to be significantly elevated in the serum and blister fluid of patients with SPD.[5, 6] However, TNF-blockers were not found to be effective in all patients, although there are reports on successful treatment with this class of drugs.[18, 19] A case of a TNF-alpha-inhibitor–induced SPD has also been described.[20]

Immunofluorescence studies are negative in the SPD of Sneddon-Wilkinson. However, a rare subtype of SPD has been reported to have a positive immunofluorescence with IgA deposition restricted to the upper epidermis and directed against desmocollin. As noted above, the clinical and histopathological characteristics have led experts to classify this variant as a variant of IgA pemphigus resembling SPD. In a large 2016 series of 49 patients with intercellular IgA dermatosis and 13 cases with SPD, it was confirmed that the SPD type of intercellular IgA dermatosis is clinically and histopathologically indistinguishable from classic SPD without immunoreactants.[7]

Additionally, despite many attempts, no infectious agent or other immunogenic trigger has yet been identified in patients with SPD. The eruption is regarded as sterile, although it may sometimes become secondarily infected with Staphylococcus aureus or streptococcal species. Preceding Mycoplasma pneumoniae infection was implicated in one report, but this case had an acute presentation that responded to 3 months of dapsone without relapse.[21]

Etiology

The etiology of subcorneal pustular dermatosis (SPD) is unknown. SPD is a sterile eruption. Because multiple subtypes have been recognized, SPD has more than one etiology.

Some cases of SPD have been considered a variant of pustular psoriasis. Note that clinical and histologic differentiation of SPD from pustular psoriasis can be difficult, although spongiform changes on histology favor the latter. Furthermore, a significant number of cases initially diagnosed as SPD are later diagnosed as psoriasis.

Other cases of SPD are argued to be a rare variant of pemphigus, known as SPD type IgA pemphigus. This subgroup of patients shows positive immunofluorescence with epidermal intercellular IgA deposits. The positive immunofluorescence can develop years after the initial diagnosis of SPD. Unlike pemphigus, a predominance of neutrophils and an absence or moderate acantholysis is observed; additionally, the condition is usually responsive to dapsone.

Epidemiology

Subcorneal pustular dermatosis (SPD) is a rare condition, and no estimate of prevalence or incidence is available. Cases have been reported worldwide, but no particular geographical predominance is apparent. SPD affects middle-aged or elderly women more commonly than men.

SPD is most common in individuals aged 40 years or older. It has been reported in children, without differences described in clinical features and prognosis between children and adults, but some cases tend to have atypical features more suggestive of psoriasis.[22, 23, 24]

Prognosis

Subcorneal pustular dermatosis (SPD) is chronic and relapsing but benign. The association of SPD with paraproteinemia or lymphoproliferative disorders, especially multiple myeloma, may alter the prognosis.

History

Subcorneal pustular dermatosis (SPD) is a benign, chronic, vesiculopustular eruption, usually affecting adults, although childhood cases have also been described.[2, 3, 4, 5] Patients typically present with a history of a relapsing pustular eruption involving the flexural areas of the trunk and proximal extremities. Individual pustular lesions arise within a few hours. Pruritus and irritation can occur but are not usually prominent symptoms. Systemic and toxic symptoms are not associated with acute episodes. However, malaise, fever, arthralgias, abnormalities of hepatic enzymes, and sclerosing glomerulonephritis have been reported in several cases.[25] Patients typically do not have any symptoms or signs of mucosal involvement.

Patients may present with histories notable for monoclonal gammopathies (IgA more often than immunoglobulin G)[8, 9] ; lymphoproliferative disorders (especially multiple myeloma)[11] ; pyoderma gangrenosum[10, 26] ;  and other inflammatory diseases such as rheumatoid arthritis,[12, 13, 27] ,systemic lupus erythematosus,[28] Sjögren syndrome,[29] diffuse scleroderma,[30] ulcerative colitis,[31] and Crohn disease.[14, 15] These conditions are well-recognized associations with SPD (developing both before and after the diagnosis of SPD). Further associations were found with other dermatoses characterized by skin infiltration with neutrophils, such as pyoderma gangrenosum and SAPHO (synovitis, acne, pustulosis, osteitis) syndrome.[32] Other anecdotally associated conditions include aplastic anemia,[33]  Mycoplasma pneumoniae infection,[34, 35, 36]  Coccidioides immitis infection,[37]  hyperthyroidism,[38] APUDoma (amine precursor uptake and decarboxylation cell–derived tumor),[39] and thymoma.[40]

Patients should be queried about a personal and family history of psoriasis, because differentiating SPD from pustular psoriasis can be difficult. Similarly, patients should be questioned about recent drug exposure because acute generalized exanthematous pustulosis is also in the differential diagnosis.[41]

Physical Examination

The primary lesions are flaccid pustules, measuring several millimeters in diameter, on normal or mildly erythematous skin. The classic lesion has been described as a "half-and-half" blister, in which purulent fluid accumulates in the lower half of the blister. New eruptions of pustules have the tendency to coalesce and often form annular, circinate, and bizarre serpiginous patterns.

See the images below.



View Image

Circinate plaques and pustules on nonerythematous base in a patient with subcorneal pustular dermatosis.



View Image

Subcorneal pustular dermatosis with numerous pustules on erythematous base.

This tends to occur symmetrically, affecting axillae, groin, abdomen, submammary areas, and the flexor side of the limbs. There are no differences in clinical features and prognosis of the disease between children and adults.[23, 24, 42] Palmar, plantar, face, and mucous membrane involvement is unusual, but is described in individual case reports.[43, 44]

The pustules can be isolated or grouped and tend to coalesce and form annular, circinate, or serpiginous patterns. The pustules are superficial and rupture easily, resulting in a superficial crust.

Mild hyperpigmentation often remains after pustular lesions have resolved.

Approach Considerations

Serum protein electrophoresis

The association of paraproteinemia with subcorneal pustular dermatosis (SPD) is well documented. One study showed 4 of 10 patients with SPD had a monoclonal gammopathy. Most reported cases have been with IgA monoclonal gammopathies, either kappa or lambda light-chain type. However, immunoglobulin G gammopathies are also reported.

Serum and urine protein electrophoresis should be repeated periodically because the development of paraproteinemia can occur years after the initial eruption of subcutaneous pustular dermatosis. Furthermore, the increased risk of multiple myeloma in patients with a monoclonal gammopathy is well recognized.

Skeletal survey and bone marrow aspiration should be undertaken if multiple myeloma is suspected.

Skin bacterial culture

Subcorneal pustular dermatosis is a sterile eruption. Impetigo and secondary bacterial infections should be excluded.

Skin scraping and fungal culture

Dermatophyte infections need to be excluded.[37]

Skin biopsy

Skin biopsy of an early lesion is needed for histologic analysis and direct immunofluorescence testing.

Histologic Findings

The classic histologic finding in subcorneal pustular dermatosis (SPD) is subcorneal pustules composed primarily of neutrophils and occasional eosinophils. However, this finding is not specific for SPD and can be found in other conditions such as pustular psoriasis, acute generalized exanthematous pustulosis, pemphigus foliaceus, bacterial impetigo, and dermatophytosis.

In SPD, unlike in pustular psoriasis, the epidermis usually has minimal spongiosis. The dermis in subcorneal pustular dermatitis shows a perivascular infiltrate of neutrophils and occasional monocytes and eosinophils. Acantholysis is not prominent; however, it has been reported in older lesions. See the image below.



View Image

Subcorneal pustules with neutrophil accumulation and minimal spongiosis.

Direct and indirect immunofluorescence studies are typically negative. Nevertheless, periodic repeat studies are recommended to detect epidermal intercellular IgA staining in order to identify a subgroup referred to as SPD type IgA pemphigus. Desmocollin-1 has been recognized as the autoantigen in this subgroup.[4, 7]

Approach Considerations

Dapsone

Dapsone is the treatment of choice. The response is slower than that seen with dermatitis herpetiformis, with resolution usually occurring in about 4 weeks. Once disease control has been established, the dose should be tapered to the lowest dose needed to maintain control. Sulfapyridine and sulfamethoxypyridazine may also be used, but only a few isolated reports support their effectiveness.

Acitretin

Acitretin (and formerly etretinate) has been used to successfully treat subcorneal pustular dermatosis (SPD) and should be considered as an alternative or additional treatment for those who are intolerant of, or unresponsive to, dapsone. Once disease control has been established, the dose should be tapered to the lowest dose needed to maintain control. Isotretinoin at 0.5 mg/kg/d appears to be ineffective.

Phototherapy

Phototherapy with psoralen with ultraviolet A (PUVA),[45] broadband ultraviolet B (UVB), and narrowband UVB alone or in combination with dapsone and/or retinoids can be successful at controlling SPD.[46] Long-term maintenance regimens may be needed.[47]

Additional therapies

Anecdotal case reports support the use of infliximab,[48] tacalcitol,[49] maxacalcitol,[50] mizoribine,[51] ketoconazole,[52] tetracycline, minocycline, benzylpenicillin, vitamin E,[53] azithromycin,[54] cyclosporine,[55, 56] colchicine,[57] pentoxifylline,[58] intravenous immunoglobulins,[59] apremilast,[60]  and adalimumab with mycophenolate mofetil.[61] Antimyeloma treatment should be considered in cases of SPD associated with IgA monoclonal gammopathy of undetermined significance, refractory to other therapies.[62]

Systemic and topical corticosteroids are generally ineffective but may provide some control. They have been used in combination with dapsone to treat associated conditions such as pyoderma gangrenosum and multiple myeloma. A good response to systemic corticosteroids is atypical and is suggestive of a diagnosis of pustular psoriasis.

Long-Term Monitoring

Long-term follow-up is recommended. Periodic evaluations with serum protein electrophoresis and direct immunofluorescence should be performed every few years.

Paraproteinemia, myeloma, intraepidermal IgA staining, and pustular psoriasis may develop several years after the initial presentation of subcorneal pustular dermatosis (SPD). Identifying these conditions, as well as other associated diagnoses, can improve the understanding of the etiology and pathogenesis of SPD, clarify its relationship with IgA pemphigus and pustular psoriasis, and help define its nosologic classification.

Medication Summary

Dapsone is the treatment of choice. Acitretin should be considered as an alternative or additional treatment for those who are intolerant of, or unresponsive to, dapsone.

Dapsone

Clinical Context:  Dapsone is a sulfone that has anti-inflammatory and immunosuppressive properties, in addition to antibacterial properties. It prevents bacterial utilization of para-aminobenzoic acid (PABA) for the synthesis of folic acid by acting as a competitive antagonist of PABA.

Acitretin (Soriatane (DSC))

Clinical Context:  Acitretin is a retinoic acid analog.

Author

Lidija Kandolf Sekulovic, MD, PhD, Professor, Head of the Department of Dermatology and Venereology, Medical Faculty, Military Medical Academy, Belgrade, Serbia

Disclosure: Nothing to disclose.

Coauthor(s)

Tanja Tirnanić, MD, Dermatovenereologist, City Institute for Skin and Venereal Diseases, Serbia

Disclosure: Nothing to disclose.

Specialty Editors

Richard P Vinson, MD, Assistant Clinical Professor, Department of Dermatology, Texas Tech University Health Sciences Center, Paul L Foster School of Medicine; Consulting Staff, Mountain View Dermatology, PA

Disclosure: Nothing to disclose.

Jeffrey P Callen, MD, Professor of Medicine (Dermatology), Chief, Division of Dermatology, University of Louisville School of Medicine

Disclosure: Received income in an amount equal to or greater than $250 from: Biogen US (Adjudicator for study entry cutaneous lupus erythematosus); Priovant (Adjudicator for entry into a dermatomyositis study); IQVIA (Serono - adjudicator for a study of cutaneous LE) <br/>Received honoraria from UpToDate for author/editor; Received royalty from Elsevier for book author/editor; Received dividends from trust accounts, but I do not control these accounts, and have directed our managers to divest pharmaceutical stocks as is fiscally prudent from Stock holdings in various trust accounts include some pharmaceutical companies and device makers for these trust accounts for: Stocks held in various trust accounts: Allergen; Amgen; Pfizer; 3M; Johnson and Johnson; Merck; Abbott Laboratories; AbbVie; Procter and Gamble;; Celgene; Gilead; CVS; Walgreens; Bristol-Myers Squibb.

Chief Editor

Dirk M Elston, MD, Professor and Chairman, Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina College of Medicine

Disclosure: Nothing to disclose.

Additional Contributors

Naveed Sami, MD, FAAD, Assistant Professor, Department of Dermatology, University of Alabama School of Medicine

Disclosure: Nothing to disclose.

Takeji Nishikawa, MD, Emeritus Professor, Department of Dermatology, Keio University School of Medicine; Director, Samoncho Dermatology Clinic; Managing Director, The Waksman Foundation of Japan Inc

Disclosure: Nothing to disclose.

Vlada Groysman, MD, Medical Director, Cahaba Dermatology and Skin Health Center; Clinical Assistant Professor of Dermatology, University of Alabama at Birmingham School of Medicine

Disclosure: Nothing to disclose.

Acknowledgements

The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous authors John D Wilkinson, MD, MBBS, MRCS, FRCP; John Reed, MBBS, MRCP; Sarah E Dick, MD; and Abby S Van Voorhees, MD, to the development and writing of the source articles.

References

  1. Sneddon IB, Wilkinson DS. Subcorneal pustular dermatosis. Br J Dermatol. 1956 Dec. 68(12):385-94. [View Abstract]
  2. Sneddon IB, Wilkinson DS. Subcorneal pustular dermatosis. Br J Dermatol. 1979 Jan. 100(1):61-8. [View Abstract]
  3. Bordignon M, Zattra E, Montesco MC, Alaibac M. Subcorneal pustular dermatosis (Sneddon-Wilkinson disease) with absence of desmoglein 1 and 3 antibodies: case report and literature review. Am J Clin Dermatol. 2008. 9(1):51-5. [View Abstract]
  4. Hashimoto T, Kiyokawa C, Mori O, et al. Human desmocollin 1 (Dsc1) is an autoantigen for the subcorneal pustular dermatosis type of IgA pemphigus. J Invest Dermatol. 1997 Aug. 109(2):127-31. [View Abstract]
  5. Grob JJ, Mege JL, Capo C, et al. Role of tumor necrosis factor-alpha in Sneddon-Wilkinson subcorneal pustular dermatosis. A model of neutrophil priming in vivo. J Am Acad Dermatol. 1991 Nov. 25(5 Pt 2):944-7. [View Abstract]
  6. Ono S, Otsuka A, Miyachi Y, Kabashima K. Subcorneal Pustular Dermatosis Exhibiting a High Serum TARC/CCL17 Level. Case Rep Dermatol. 2013 Jan. 5(1):38-42. [View Abstract]
  7. Hashimoto T, Teye K, Ishii N. Clinical and immunological studies of 49 cases of various types of intercellular IgA dermatosis and 13 cases of classical subcorneal pustular dermatosis examined at Kurume University. Br J Dermatol. 2017 Jan. 176 (1):168-75. [View Abstract]
  8. Kasha EE Jr, Epinette WW. Subcorneal pustular dermatosis (Sneddon-Wilkinson disease) in association with a monoclonal IgA gammopathy: a report and review of the literature. J Am Acad Dermatol. 1988 Nov. 19(5 Pt 1):854-8. [View Abstract]
  9. Wallach D, Cottenot F, Pelbois G, Cavelier B, Didierjean L, Saurat JH. Subcorneal pustular dermatosis and monoclonal IgA. Br J Dermatol. 1982 Aug. 107(2):229-34. [View Abstract]
  10. Puechguiral-Renaud I, Carpentier O, Piette F, Delaporte E. Subcorneal pustulosis and Pyoderma gangrenosum associated with a biclonal gammopathy. Eur J Dermatol. 2006 Nov-Dec. 16(6):687-90. [View Abstract]
  11. Takata M, Inaoki M, Shodo M, Hirone T, Kaya H. Subcorneal pustular dermatosis associated with IgA myeloma and intraepidermal IgA deposits. Dermatology. 1994. 189 Suppl 1:111-4. [View Abstract]
  12. Butt A, Burge SM. Sneddon-Wilkinson disease in association with rheumatoid arthritis. Br J Dermatol. 1995 Feb. 132(2):313-5. [View Abstract]
  13. Lin RY, Schwartz RA, Lambert WC. Subcorneal pustular dermatosis with polyarthritis. Cutis. 1986 Feb. 37(2):123-4, 126. [View Abstract]
  14. Delaporte E, Colombel JF, Nguyen-Mailfer C, Piette F, Cortot A, Bergoend H. Subcorneal pustular dermatosis in a patient with Crohn's disease. Acta Derm Venereol. 1992 Aug. 72 (4):301-2. [View Abstract]
  15. García-Salces I, Baldellou R, Hörndler C, Zubiri ML. Subcorneal pustular dermatosis with pathergy phenomenon in a patient with Crohn's disease. J Eur Acad Dermatol Venereol. 2009 Mar. 23 (3):349-50. [View Abstract]
  16. Cohen PR. Neutrophilic dermatoses: a review of current treatment options. Am J Clin Dermatol. 2009. 10 (5):301-12. [View Abstract]
  17. Naik HB, Cowen EW. Autoinflammatory pustular neutrophilic diseases. Dermatol Clin. 2013 Jul. 31 (3):405-25. [View Abstract]
  18. Voigtlander C, Luftl M, Schuler G, Hertl M. Infliximab (anti-tumor necrosis factor alpha antibody): a novel, highly effective treatment of recalcitrant subcorneal pustular dermatosis (Sneddon-Wilkinson disease). Arch Dermatol. 2001 Dec. 137(12):1571-4. [View Abstract]
  19. Bonifati C, Trento E, Cordiali Fei P, Muscardin L, Amantea A, Carducci M. Early but not lasting improvement of recalcitrant subcorneal pustular dermatosis (Sneddon-Wilkinson disease) after infliximab therapy: relationships with variations in cytokine levels in suction blister fluids. Clin Exp Dermatol. 2005 Nov. 30(6):662-5. [View Abstract]
  20. Sauder MB, Glassman SJ. Palmoplantar subcorneal pustular dermatosis following adalimumab therapy for rheumatoid arthritis. Int J Dermatol. 2013 May. 52 (5):624-8. [View Abstract]
  21. Papini M, Cicoletti M, Landucci P. Subcorneal pustular dermatosis and mycoplasma pneumoniae respiratory infection. Acta Derm Venereol. 2003. 83(5):387-8. [View Abstract]
  22. Scalvenzi M, Palmisano F, Annunziata MC, Mezza E, Cozzolino I, Costa C. Subcorneal pustular dermatosis in childhood: a case report and review of the literature. Case Rep Dermatol Med. 2013. 2013:424797. [View Abstract]
  23. Johnson SA, Cripps DJ. Subcorneal pustular dermatosis in children. Arch Dermatol. 1974 Jan. 109 (1):73-7. [View Abstract]
  24. Koçak M, Birol A, Erkek E, Bozdoğan O, Atasoy P. Juvenile subcorneal pustular dermatosis: a case report. Pediatr Dermatol. 2003 Jan-Feb. 20 (1):57-9. [View Abstract]
  25. Watts PJ, Khachemoune A. Subcorneal Pustular Dermatosis: A Review of 30 Years of Progress. Am J Clin Dermatol. 2016 Dec. 17 (6):653-671. [View Abstract]
  26. Scerri L, Zaki I, Allen BR. Pyoderma gangrenosum and subcorneal pustular dermatosis, without monoclonal gammopathy. Br J Dermatol. 1994 Mar. 130(3):398-9. [View Abstract]
  27. Iobst W, Ingraham K. Sneddon-Wilkinson disease in a patient with rheumatoid arthritis. Arthritis Rheum. 2005 Dec. 52(12):3771. [View Abstract]
  28. Saulsbury FT, Kesler RW. Subcorneal pustular dermatosis and systemic lupus erythematosus. Int J Dermatol. 1984 Jan-Feb. 23 (1):63-4. [View Abstract]
  29. Tsuruta D, Matsumura-Oura A, Ishii M. Subcorneal pustular dermatosis and Sjögren's syndrome. Int J Dermatol. 2005 Nov. 44(11):955-7. [View Abstract]
  30. Mokhtari F, Poostiyan N. Subcorneal Pustular Dermatosis: A Case Report of a Patient with Diffuse Scleroderma. Adv Biomed Res. 2018. 7:83. [View Abstract]
  31. Wargo JJ, Adams M, Trevino J. Subcorneal pustular dermatosis and episcleritis associated with poorly controlled ulcerative colitis. BMJ Case Rep. 2017 Jan 30. 2017:[View Abstract]
  32. Scarpa R, Lubrano E, Cozzi R, Ames PR, Oriente CB, Oriente P. Subcorneal pustular dermatosis (Sneddon-Wilkinson syndrome): another cutaneous manifestation of SAPHO syndrome?. Br J Rheumatol. 1997 May. 36 (5):602-3. [View Abstract]
  33. Park BS, Cho KH, Eun HC, Youn JI. Subcorneal pustular dermatosis in a patient with aplastic anemia. J Am Acad Dermatol. 1998 Aug. 39 (2 Pt 1):287-9. [View Abstract]
  34. Lombart F, Dhaille F, Lok C, Dadban A. Subcorneal pustular dermatosis associated with Mycoplasma pneumoniae infection. J Am Acad Dermatol. 2014 Sep. 71 (3):e85-6. [View Abstract]
  35. Papini M, Cicoletti M, Landucci P. Subcorneal pustular dermatosis and mycoplasma pneumoniae respiratory infection. Acta Derm Venereol. 2003. 83 (5):387-8. [View Abstract]
  36. Lombart F, Dhaille F, Lok C, Dadban A. Subcorneal pustular dermatosis associated with Mycoplasma pneumoniae infection. J Am Acad Dermatol. 2014 Sep. 71 (3):e85-6. [View Abstract]
  37. Iyengar S, Chambers CJ, Chang S, Fung MA, Sharon VR. Subcorneal pustular dermatosis associated with Coccidioides immitis. Dermatol Online J. 2015 Aug 15. 21 (8):[View Abstract]
  38. Taniguchi S, Tsuruta D, Kutsuna H, Hamada T. Subcorneal pustular dermatosis in a patient with hyperthyroidism. Dermatology. 1995. 190 (1):64-6. [View Abstract]
  39. Villey MC, Ehrsam E, Marrakchi S, Colombel JF, Thomas P. Apudoma and subcorneal pustular dermatosis (Sneddon-Wilkinson disease). Dermatology. 1992. 185 (4):269-71. [View Abstract]
  40. Agarwal A, Shivaswamy KN, Barani R et al. Subcorneal pustular dermatosis and thymoma:an association or a coincidence?. Indian J Dermatol. 2006. 51:272-4.
  41. Tajiri K, Nakajima T, Kawai K, Minemura M, Sugiyama T. Sneddon-Wilkinson disease induced by sorafenib in a patient with advanced hepatocellular carcinoma. Intern Med. 2015. 54 (6):597-600. [View Abstract]
  42. Scalvenzi M, Palmisano F, Annunziata MC, Mezza E, Cozzolino I, Costa C. Subcorneal pustular dermatosis in childhood: a case report and review of the literature. Case Rep Dermatol Med. 2013. 2013:424797. [View Abstract]
  43. Sauder MB, Glassman SJ. Palmoplantar subcorneal pustular dermatosis following adalimumab therapy for rheumatoid arthritis. Int J Dermatol. 2013 May. 52(5):624-8. [View Abstract]
  44. Lotery HE, Eedy DJ, McCusker G. Subcorneal pustular dermatosis involving the face. J Eur Acad Dermatol Venereol. 1999 May. 12 (3):230-3. [View Abstract]
  45. Bauwens M, De Coninck A, Roseeuw D. Subcorneal pustular dermatosis treated with PUVA therapy. A case report and review of the literature. Dermatology. 1999. 198(2):203-5. [View Abstract]
  46. Orton DI, George SA. Subcorneal pustular dermatosis responsive to narrowband (TL-01) UVB phototherapy. Br J Dermatol. 1997 Jul. 137(1):149-50. [View Abstract]
  47. Marliere V, Beylot-Barry M, Beylot C, Doutre M. Successful treatment of subcorneal pustular dermatosis (Sneddon-wilkinson disease) by acitretin: report of a case. Dermatology. 1999. 199(2):153-5. [View Abstract]
  48. Romagnuolo M, Muratori S, Cattaneo A, Marzano AV, Moltrasio C. Successful treatment of refractory Sneddon-Wilkinson disease (subcorneal pustular dermatosis) with infliximab. Dermatol Ther. 2022 Jul. 35 (7):e15552. [View Abstract]
  49. Kawaguchi M, Mitsuhashi Y, Kondo S. A case of subcorneal pustular dermatosis treated with tacalcitol (1alpha,24-dihydroxyvitamin D3). J Dermatol. 2000 Oct. 27(10):669-72. [View Abstract]
  50. Hoshina D, Tsujiwaki M, Furuya K. Successful treatment of subcorneal pustular dermatosis with maxacalcitol. Clin Exp Dermatol. 2016 Jan. 41 (1):102-3. [View Abstract]
  51. Kono T, Terashima T, Oura H, Ishii M, Taniguchi S, Muramatsu T. Recalcitrant subcorneal pustular dermatosis and bullous pemphigoid treated with mizoribine, an immunosuppressive, purine biosynthesis inhibitor. Br J Dermatol. 2000 Dec. 143(6):1328-30. [View Abstract]
  52. Verma KK, Pasricha JS. Ketoconazole as a therapeutic modality in subcorneal pustular dermatosis. Acta Derm Venereol. 1997 Sep. 77(5):407-8. [View Abstract]
  53. Ayres S Jr, Mihan R. Letter: Subcorneal pustular dermatosis controlled by vitamin E. Arch Dermatol. 1974 Jun. 109(6):914. [View Abstract]
  54. Bliziotis I, Rafailidis P, Vergidis P, Falagas ME. Regression of subcorneal pustular dermatosis type of IgA pemphigus lesions with azithromycin. J Infect. 2005 Aug. 51(2):E31-4. [View Abstract]
  55. Zachariae CO, Rossen K, Weismann K. An unusual severe case of subcorneal pustular dermatosis treated with cyclosporine and prednisolone. Acta Derm Venereol. 2000 Sep-Oct. 80(5):386-7. [View Abstract]
  56. Karadogan SK, Aydogan K, Baskan EB, Tunali S. A case of subcorneal pustular dermatosis treated successfully with a combination of cyclosporin and prednisolone. J Eur Acad Dermatol Venereol. 2007 Apr. 21(4):536-7. [View Abstract]
  57. Wanberg LJ, Schultz B, Goyal A. Treatment of Subcorneal Pustular Dermatosis without Dapsone: A Case Report and Review of the Literature. Case Rep Dermatol Med. 2024. 2024:8140483. [View Abstract]
  58. Falcone LM, Pilcher MF, Kovach RF, Powers R. Pentoxyfilline as a Treatment for Subcorneal Pustular Dermatosis. Dermatol Ther. 2019 Jan 14. e12818. [View Abstract]
  59. Kundak S, Bağ Ö, Gülez N, Ergin M. A child with subcorneal pustular dermatosis responded to IVIG treatment (Sneddon-Wilkinson disease). Reumatologia. 2017. 55 (6):323-327. [View Abstract]
  60. Bettolini L, Bighetti S, Incardona P, Calzavara-Pinton P, Maione V. Successful Treatment of Recalcitrant Subcorneal Pustular Dermatosis (Sneddon-Wilkinson Diseases) With Apremilast. Dermatol Pract Concept. 2024 Jan 1. 14 (1):[View Abstract]
  61. Howell SM, Bessinger GT, Altman CE, Belnap CM. Rapid response of IgA pemphigus of the subcorneal pustular dermatosis subtype to treatment with adalimumab and mycophenolate mofetil. J Am Acad Dermatol. 2005 Sep. 53(3):541-3. [View Abstract]
  62. von dem Borne PA, Jonkman MF, van Doorn R. Complete remission of skin lesions in a patient with subcorneal pustular dermatosis (Sneddon-Wilkinson disease) treated with antimyeloma therapy: association with disappearance of M-protein. Br J Dermatol. 2017 May. 176 (5):1341-1344. [View Abstract]

Circinate plaques and pustules on nonerythematous base in a patient with subcorneal pustular dermatosis.

Circinate plaques and pustules on nonerythematous base in a patient with subcorneal pustular dermatosis.

Subcorneal pustular dermatosis with numerous pustules on erythematous base.

Subcorneal pustules with neutrophil accumulation and minimal spongiosis.

Circinate plaques and pustules on nonerythematous base in a patient with subcorneal pustular dermatosis.

Subcorneal pustular dermatosis with numerous pustules on erythematous base.

Subcorneal pustules with neutrophil accumulation and minimal spongiosis.